摘要
核苷(酸)类似物可有效阻止或延缓慢性HBV感染者的疾病进展,但其疗程长且长期用药存在一定的药物副反应及耐药风险。近期研究发现HBsAg定量对慢性乙型肝炎患者的个体化抗病毒治疗有重要意义。就目前HBsAg定量在核苷(酸)类似物抗HBV治疗的指征评判、疗效预测及停药把握等方面的研究进展进行综述,认为HBsAg定量不仅有利于合理选择抗病毒治疗时机,而且有利于在抗病毒治疗开始时、治疗过程中以及考虑停药时预测患者可能疗效。但是对于HBeAg阳性或阴性感染者各病程分期的最佳预测阈值和不同核苷(酸)类似物抗病毒治疗过程中疗效预测的最佳时间点与最佳预测阈值仍值得进一步研究。
Nucleos(t)ide analogues can effectively prevent or delay disease progression in patients with chronic hepatitis B virus (HBV) infection, but the course of treatment is long and long-term medication may bring the risk of adverse drug reactions and drug resistance. Recent studies have found that HBsAg quantification has an important value in individualized antiviral treatment for patients with chronic hepatitis B. This article reviews the research advances in the value of HBsAg quantification in judgment of indication for antiviral treatment with nucleos(t)ide analogues, prediction of therapeutic outcome, and timing of drug withdrawal, and it is pointed out that HBsAg quantification can help to determine the timing of antiviral treatment and predict the treatment outcome of patients at the beginning of antiviral treatment, during the treatment process, and when drug withdrawal is considered. Further studies are needed to determine the optimal predictive thresholds for different stages of HBeAg-positive or HBeAg-negative patients, as well as the optimal time point and thresholds for predicting treatment outcome during antiviral treatment with different nucleos(t)ide analogues.
作者
周友乾
李翠
ZHOU Youqian;LI Cui(Department of Infectious Diseases, 922 Hospital of PLA & Xiangnan Hospital Affiliated to Hunan Normal University, Hengyang, Hunan 421002, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2019年第8期1821-1823,共3页
Journal of Clinical Hepatology
基金
湖南省卫生计生委课题(C2016096)
